According to the 2012 China Tumor Annual Report statistics, malignant lymphoma is one of the top 10 malignant tumors in China in terms of incidence and is growing at an annual rate of 4%, making it one of the fastest growing tumors in China, of which there are two major categories, B-cell lymphoma and T-cell lymphoma. T-cell lymphoma is a heterogeneous group of diseases with different biological features and clinical manifestations, including systemic symptoms and extensive generalized lymph node enlargement, skin and liver, spleen and bone marrow involvement. Compared to B-cell lymphoma, it is characterized by aggressive disease, poor response to drug therapy, and poor prognosis. Pathologic biopsy can lead to a definitive diagnosis. The 2008 WHO lymphoma classification classifies T-cell lymphomas according to morphologic, immunophenotypic, genetic and clinical features, of which peripheral T-cell lymphomas are the most common non-specific, which also include mesenchymal large cell lymphoma and angioimmunoblastoma T-cell lymphoma. To date, there is no clear and effective treatment regimen for T-cell lymphoma. M. D. Anderson in the United States explored the application of multiple intensive regimens for T-cell lymphoma, and compared with the CHOP regimen, the 3-year overall survival was 43% for the CHOP regimen and 49% for the intensive regimen. The role and place of autologous stem cell transplantation in the treatment of T-cell lymphoma is unknown. Numerous studies suggest that autologous stem cell transplantation is safe as consolidation therapy after remission of T-cell lymphoma induction therapy, that transplantation-related mortality is below 5%, and that ASCT as consolidation therapy appears to improve outcomes in patients with high-risk peripheral T-cell lymphoma. The efficacy of using autologous stem cell transplantation as salvage therapy for T-cell lymphoma is similar to that of aggressive B-cell lymphoma, with 3-year overall and event-free survival rates of 58% and 48%, respectively. Allogeneic hematopoietic stem cell transplantation for T-cell lymphoma has been poorly reported, and small studies have shown that transplantation in the chemotherapy-sensitive group is superior to that in the chemoresistant group. Studies to explore the best treatment options are currently underway. The following is a case in our department. Lin**, a 57-year-old male, had swollen superficial lymph nodes with high fever, rash and itching, and relied on antipyretics and hormones to maintain his body temperature and relieve skin symptoms. After two courses of treatment, the rash subsided and the itchy skin disappeared, and anti-allergic drugs such as hormones were completely stopped. The patient continued to apply arsenic trioxide during the maintenance period, and the disease is still in remission 2 years after the onset of the disease.